Home - Longevity.Technology

Cellular

Promising restorative therapy potentially 5 years away

Margaretta Colangelo - January 22, 2021

Wellness

Longevity Escape Velocity within 10 years?

Eleanor Garth - January 22, 20210

Bestselling book enters new markets and predicts Longevity Escape Velocity by 2029/30. Back in the 1980s, pop sensation Wham! encouraged us all to "Choose Life";...

Cellular

“Adjust the immune system… de-age the brain”

Danny Sullivan - January 21, 20210

Stanford study finds that blocking certain interactions on immune cells reverses age-related mental decline in older mice. Stanford University researchers have published a new study...

A long-awaited Deep-SeSMo AI approach can now be implemented in screening for anti-senescence cell drug candidates.

Development

AI to quantify senescent cell counts

Eleanor Garth - January 21, 2021 0

A long-awaited AI approach can now be implemented in screening for anti-senescence drug candidates. Developing a...

Rubedo’s first senolytic target is respiratory disease, with COVID-19 expected to drive an increase in lung disease over the next 10 years.

Senolytic drugs

Senolytic start-up gears up for clinical trials

Danny Sullivan - January 20, 2021 0

Rubedo’s first target is respiratory disease, with COVID-19 expected to drive an increase in lung...

Risk scores could become a routine personal genomics prediction method for lifelong health planning and disease prevention.

Cellular

Predicting Longevity using polygenic risk scores

Christos Evangelou - January 20, 2021 0

Health and disease prediction scores could become a routine personal genomics risk prediction method for...

Gerostate Alpha's founders talk increasing lifespan, drug discovery, indications and raising funding for anti-aging interventions.

Development

Gerostate Alpha: “Our phenotype is lifespan”

Danny Sullivan - January 19, 2021 0

Buck Institute start-up's founders talk drug discovery, indications and raising funding. Following yesterday's introduction to Gerostate...

CohBar and NIAID announce that they are set to assess CB5064 Analogues for COVID-19 and respiratory distress treatment.

Development

CohBar announces preclinical collaboration with NIAID

Eleanor Garth - January 19, 2021 0

CohBar and NIAID set to assess CB5064 Analogues for COVID-19 and respiratory distress treatment. Clinical stage...